Significant association between the use of different proton pump inhibitors and microscopic colitis: A nationwide Danish case-control study

Ole K. Bonderup*, Gunnar L. Nielsen, Michael Dall, Anton Pottegård, Jesper Hallas

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Background: Microscopic colitis causes chronic watery diarrhoea and has previously been associated with the use of proton pump inhibitors. Aim: To explore the association between proton pump inhibitor use and microscopic colitis, including its dependency on timing, dose and choice of proton pump inhibitor. Methods: Within a 10-year period, we identified 10 652 patients with a first-time diagnosis of microscopic colitis, including 6254 (59%) with collagenous colitis and 4398 (41%) with lymphocytic colitis. All microscopic colitis cases were histologically confirmed in the Danish Pathology Register. Information on proton pump inhibitor use was obtained from the Danish Prescription Register. In this case-control study, we estimated the adjusted odds ratios (aOR) for the association between proton pump inhibitor use and risk of microscopic colitis using conditional logistic regression while adjusting for potential confounders. Results: We found strong associations between current proton pump inhibitor use and both collagenous colitis (aOR 6.98; 95% CI: 6.45-7.55) and lymphocytic colitis (aOR 3.95; 95% CI: 3.60-4.33). This association was observed with all PPIs. The strongest association was with the current use of lansoprazole for both collagenous colitis (aOR 15.74; 95% CI: 14.12-17.55) and lymphocytic colitis (aOR 6.87; 95% CI: 6.00-7.86). When considering timing, ORs were highest for current use of proton pump inhibitor and lower for recent or past exposure. No clear dose-response pattern was observed. Conclusions: We found a strong association between microscopic colitis and ongoing use of proton pump inhibitors, especially lansoprazole.

OriginalsprogEngelsk
TidsskriftAlimentary Pharmacology and Therapeutics
Vol/bind48
Udgave nummer6
Sider (fra-til)618-625
ISSN0269-2813
DOI
StatusUdgivet - 2018

Fingeraftryk

Case-Control Studies
Odds Ratio
Prescriptions
Logistic Models
Pathology

Citer dette

@article{4f648bbdc21b42d78f22626f9c133540,
title = "Significant association between the use of different proton pump inhibitors and microscopic colitis: A nationwide Danish case-control study",
abstract = "Background: Microscopic colitis causes chronic watery diarrhoea and has previously been associated with the use of proton pump inhibitors. Aim: To explore the association between proton pump inhibitor use and microscopic colitis, including its dependency on timing, dose and choice of proton pump inhibitor. Methods: Within a 10-year period, we identified 10 652 patients with a first-time diagnosis of microscopic colitis, including 6254 (59{\%}) with collagenous colitis and 4398 (41{\%}) with lymphocytic colitis. All microscopic colitis cases were histologically confirmed in the Danish Pathology Register. Information on proton pump inhibitor use was obtained from the Danish Prescription Register. In this case-control study, we estimated the adjusted odds ratios (aOR) for the association between proton pump inhibitor use and risk of microscopic colitis using conditional logistic regression while adjusting for potential confounders. Results: We found strong associations between current proton pump inhibitor use and both collagenous colitis (aOR 6.98; 95{\%} CI: 6.45-7.55) and lymphocytic colitis (aOR 3.95; 95{\%} CI: 3.60-4.33). This association was observed with all PPIs. The strongest association was with the current use of lansoprazole for both collagenous colitis (aOR 15.74; 95{\%} CI: 14.12-17.55) and lymphocytic colitis (aOR 6.87; 95{\%} CI: 6.00-7.86). When considering timing, ORs were highest for current use of proton pump inhibitor and lower for recent or past exposure. No clear dose-response pattern was observed. Conclusions: We found a strong association between microscopic colitis and ongoing use of proton pump inhibitors, especially lansoprazole.",
author = "Bonderup, {Ole K.} and Nielsen, {Gunnar L.} and Michael Dall and Anton Potteg{\aa}rd and Jesper Hallas",
year = "2018",
doi = "10.1111/apt.14916",
language = "English",
volume = "48",
pages = "618--625",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

Significant association between the use of different proton pump inhibitors and microscopic colitis : A nationwide Danish case-control study. / Bonderup, Ole K.; Nielsen, Gunnar L.; Dall, Michael; Pottegård, Anton; Hallas, Jesper.

I: Alimentary Pharmacology and Therapeutics, Bind 48, Nr. 6, 2018, s. 618-625.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Significant association between the use of different proton pump inhibitors and microscopic colitis

T2 - A nationwide Danish case-control study

AU - Bonderup, Ole K.

AU - Nielsen, Gunnar L.

AU - Dall, Michael

AU - Pottegård, Anton

AU - Hallas, Jesper

PY - 2018

Y1 - 2018

N2 - Background: Microscopic colitis causes chronic watery diarrhoea and has previously been associated with the use of proton pump inhibitors. Aim: To explore the association between proton pump inhibitor use and microscopic colitis, including its dependency on timing, dose and choice of proton pump inhibitor. Methods: Within a 10-year period, we identified 10 652 patients with a first-time diagnosis of microscopic colitis, including 6254 (59%) with collagenous colitis and 4398 (41%) with lymphocytic colitis. All microscopic colitis cases were histologically confirmed in the Danish Pathology Register. Information on proton pump inhibitor use was obtained from the Danish Prescription Register. In this case-control study, we estimated the adjusted odds ratios (aOR) for the association between proton pump inhibitor use and risk of microscopic colitis using conditional logistic regression while adjusting for potential confounders. Results: We found strong associations between current proton pump inhibitor use and both collagenous colitis (aOR 6.98; 95% CI: 6.45-7.55) and lymphocytic colitis (aOR 3.95; 95% CI: 3.60-4.33). This association was observed with all PPIs. The strongest association was with the current use of lansoprazole for both collagenous colitis (aOR 15.74; 95% CI: 14.12-17.55) and lymphocytic colitis (aOR 6.87; 95% CI: 6.00-7.86). When considering timing, ORs were highest for current use of proton pump inhibitor and lower for recent or past exposure. No clear dose-response pattern was observed. Conclusions: We found a strong association between microscopic colitis and ongoing use of proton pump inhibitors, especially lansoprazole.

AB - Background: Microscopic colitis causes chronic watery diarrhoea and has previously been associated with the use of proton pump inhibitors. Aim: To explore the association between proton pump inhibitor use and microscopic colitis, including its dependency on timing, dose and choice of proton pump inhibitor. Methods: Within a 10-year period, we identified 10 652 patients with a first-time diagnosis of microscopic colitis, including 6254 (59%) with collagenous colitis and 4398 (41%) with lymphocytic colitis. All microscopic colitis cases were histologically confirmed in the Danish Pathology Register. Information on proton pump inhibitor use was obtained from the Danish Prescription Register. In this case-control study, we estimated the adjusted odds ratios (aOR) for the association between proton pump inhibitor use and risk of microscopic colitis using conditional logistic regression while adjusting for potential confounders. Results: We found strong associations between current proton pump inhibitor use and both collagenous colitis (aOR 6.98; 95% CI: 6.45-7.55) and lymphocytic colitis (aOR 3.95; 95% CI: 3.60-4.33). This association was observed with all PPIs. The strongest association was with the current use of lansoprazole for both collagenous colitis (aOR 15.74; 95% CI: 14.12-17.55) and lymphocytic colitis (aOR 6.87; 95% CI: 6.00-7.86). When considering timing, ORs were highest for current use of proton pump inhibitor and lower for recent or past exposure. No clear dose-response pattern was observed. Conclusions: We found a strong association between microscopic colitis and ongoing use of proton pump inhibitors, especially lansoprazole.

U2 - 10.1111/apt.14916

DO - 10.1111/apt.14916

M3 - Journal article

C2 - 30039564

AN - SCOPUS:85050930359

VL - 48

SP - 618

EP - 625

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -